AstraZeneca Wins Reversal of $107.5M Verdict in Pfizer Patent Case Over Tagrisso and Nerlynx

Aug 15, 2024, 02:45 PM

AstraZeneca has successfully overturned a $107.5 million jury verdict in a U.S. patent dispute with Pfizer. The case involved allegations that AstraZeneca's cancer drug, Tagrisso, infringed on patents related to Pfizer's breast-cancer drug, Nerlynx. A federal judge, Matthew Kennelly, ruled that the patents in question were invalid due to insufficient information about the invention. Pfizer, which acquired Wyeth in 2009, had originally sued AstraZeneca in 2021. The decision marks a legal victory for AstraZeneca, represented by Covington, over Pfizer's legal team, Jones Day.